This is a working overview of glucagon receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-26 and is reviewed periodically as new material appears.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
The fake news, fueled by disinformation, mainly from right-wing figures such as Nikolas Ferreira, which circulated widely, was denied both by the government and by the Federal Revenue Service, the Central Bank, and news outlets. Despite the denials, the negative repercussions affected users' confidence, resulting in the biggest drop in the use of Pix since the creation of the system. Between 4 and 10 January 2025, 1.25 billion reais in Pix transactions were carried out, a reduction of almost 11% compared with December. This was the largest monthly drop recorded since January 2022. However, according to the Central Bank, the drop was not related to the wave of fake news, but rather to Christmas. On 15 January 2025, after the negative repercussions, the Minister of Finance, Fernando Haddad, announced that the government would revoke the act that expanded the oversight of the Federal Revenue Service over the new financial transactions. Haddad also stated that the president would sign a provisional measure to guarantee that Pix cannot be taxed. Later, the Federal Revenue Service pointed out that the revocation of the oversight weakened the monitoring of financial operations and favored organized crime organizations, and Robinson Barreirinhas, special secretary of the agency, stated that the Federal Revenue Service suffered "the greatest attack in its history" when he wrote: "We published this instruction in September of last year [2024], to take effect from January. What happened in January we all know.
The decreased oxytocin receptor levels were associated with behavioral changes including increased aggression and anxiety-like behavior, hyperactivity, and diminished social behaviors and memory. Exogenous administration of oxytocin receptor agonists like oxytocin or TGOT was able to partially reverse the behavioral changes. Fecal microbiota transplant from people with social anxiety disorder into rodents caused selective social anxiety-like symptoms in the rodents. This was associated with brain oxytocinergic abnormalities, including decreased expression of the oxytocin receptor. Lactobacillus reuteri has been found to increase oxytocinergic signaling in rodents, with its metabolite ergothioneine reducing social avoidance behavior. Conversely, propionic acid (propionate), which is produced by certain gut bacteria and is increased by social isolation, has been found to induce social deficits and anxiety in rodents, with this being associated with decreased oxytocin receptor expression. In some mammals, oxytocin receptors are also found in the kidney and heart.
Compared to the City of Toronto as a whole, industry in the district is similar in all labour force categories, save for manufacturing which is higher in the district, and professional, scientific and technical services which are lower. Notable companies that have their headquarters in the district include Toyota Canada, Owens Corning (Toronto), Elizabeth Grant International, Enterprise Holdings, Inc., Thomson Carswell, Bell Media, Teva Canada, Cinram, Royal Doulton, SKF, Amphenol, Dart Canada, Mastermind Toys, Alfa Laval, President's Choice Financial, Aviva, Yellow Pages Group, Telus, and Lee Kum Kee Canada. The pizza chains 241 Pizza and Pizza Nova have their headquarters in Scarborough. Amazon opened a new fulfillment centre in north Scarborough in 2020. Large companies that have moved out of Scarborough include: General Motors Canada Van Assembly plant (1993) and Eli Lilly Canada (2019). A high-density business district has been built up in Scarborough City Centre. Points of interest in the area include Scarborough Town Centre, Albert Campbell Square, Street Eats Market, many surrounding stores, and government and business offices. The area has become one of Toronto's secondary business districts outside of Downtown Toronto.
=== Dextran prodrug applications === These drug-polymer complexes have advantages such as longer drug half-life and improved targeted drug delivery. Dextran prodrugs have potential applications in the treatment of liver diseases, pulmonary diseases, colonic diseases, and cancer.
==== Dengue epidemic ==== In 2024, the number of deaths from dengue in the country surged (6,041), an increase of 400% compared with 2023 (1,179), surpassing the deaths from COVID-19 (5,960) in that year (2024). Dengue deaths in 2024 exceeded the total for the previous eight years (4,992). The explosion in dengue cases led opposition deputies from the PL to nickname Lula "presidengue" and share false and exaggerated data about the number of deaths resulting from this small-scale epidemic.
Sources: en.wikipedia.org
Mifamurtide (trade name Mepact, marketed by Takeda) is a drug against osteosarcoma, a kind of bone cancer mainly affecting children and young adults, which is lethal in over half of cases. The drug was approved in Europe in March 2009.
Uranium-238 is predominantly an alpha emitter, decaying to thorium-234. It ultimately decays through the uranium series, which has 18 members, into lead-206. Uranium-238 is not fissile, but is a fertile isotope, because after neutron activation it can be converted to plutonium-239, another fissile isotope. Indeed, the 238U nucleus can absorb one neutron to produce the radioactive isotope uranium-239. 239U decays by beta emission to neptunium-239, also a beta-emitter, that decays in its turn, within a few days into plutonium-239. 239Pu was used as fissile material in the first atomic bomb detonated in the "Trinity test" on 16 July 1945 in New Mexico. Uranium-235 has a half-life of about 7.04×108 years; it is the next most stable uranium isotope after 238U and is also predominantly an alpha emitter, decaying to thorium-231. Uranium-235 is important for both nuclear reactors and nuclear weapons, because it is the only uranium isotope existing in nature on Earth in significant amounts that is fissile. This means that it can be split into two or three fragments (fission products) by thermal neutrons. The decay chain of 235U, which is called the actinium series, has 15 members and eventually decays into lead-207. The constant rates of decay in these decay series makes the comparison of the ratios of parent to daughter elements useful in radiometric dating. Uranium-236 has a half-life of 2.342×107 years and is not found in significant quantities in nature.
IP3, DAG, and Ca2+ are second messengers in the phosphoinositol pathway. The pathway begins with the binding of extracellular primary messengers such as epinephrine, acetylcholine, and hormones AGT, GnRH, GHRH, oxytocin, and TRH, to their respective receptors. Epinephrine binds to the α1 GTPase Protein Coupled Receptor (GPCR) and acetylcholine binds to M1 and M2 GPCR. Binding of a primary messenger to these receptors results in conformational change of the receptor. The α subunit, with the help of guanine nucleotide exchange factors (GEFS), releases GDP, and binds GTP, resulting in the dissociation of the subunit and subsequent activation. The activated α subunit activates phospholipase C, which hydrolyzes membrane bound phosphatidylinositol 4,5-bisphosphate (PIP2), resulting in the formation of secondary messengers diacylglycerol (DAG) and inositol-1,4,5-triphosphate (IP3). IP3 binds to calcium pumps on ER, transporting Ca2+, another second messenger, into the cytoplasm. Ca2+ ultimately binds to many proteins, activating a cascade of enzymatic pathways.
Bromley is a large town in Greater London, England, within the London Borough of Bromley. It is 9+1⁄2 miles (15 kilometres) southeast of Charing Cross, and had an estimated population of 97,540 as of 2021. Originally part of Kent, Bromley became a market town, chartered in 1158. Its location on a coaching route and the opening of a railway station in 1858 were key to its development and the shift from an agrarian village to an urban town. As part of the growth of London's conurbation in the 20th century, Bromley Town significantly increased in population and was incorporated as a municipal borough in 1903 and became part of the London Borough of Bromley in 1965. Bromley today forms a major retail and commercial centre. It is identified in the London Plan as one of the 13 metropolitan centres of Greater London.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。